ULTRAGENYX PHARMACEUTICAL INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 1.20 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was 1.20M shares, a 16.98% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 1.45M shares, a 31.93% decline from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 2.12M shares, a 7.44% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2022 was 2.29M shares, a 88.37% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|
| 2025-12-31 | 1.20M shares 10-K · filed 2026-02-18 |
| 2024-12-31 | 1.45M shares 10-K · filed 2025-02-19 |
| 2023-12-31 | 2.12M shares 10-K · filed 2024-02-21 |
| 2022-12-31 | 2.29M shares 10-K · filed 2023-02-17 |
| 2021-12-31 | 1.22M shares 10-K · filed 2022-02-15 |
| 2020-12-31 | 1.85M shares 10-K · filed 2022-02-15 |
| 2019-12-31 | 1.76M shares 10-K · filed 2022-02-15 |
| 2018-12-31 | 1.48M shares 10-K · filed 2021-02-12 |
| 2017-12-31 | 1.33M shares 10-K · filed 2020-02-14 |
| 2016-12-31 | 1.44M shares 10-K · filed 2019-02-20 |
| 2015-12-31 | 2.01M shares 10-K · filed 2018-02-21 |
| 2014-12-31 | 932.55K shares 10-K · filed 2017-02-17 |
| 2013-12-31 | 1.27M shares 10-K · filed 2016-02-26 |
| 2012-12-31 | 499.28K shares 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |